Oncology Venture – Latest news

MedWatch article from 3 August 2017

Lovende studie bringer Oncology Venture nærmere første lægemiddel (Danish)
Oncology Venture närmar sig sitt första läkemedel efter en lovande studie (Swedish)


Aktieinfo publishes analysis on Oncology Venture

Read the analysis (Danish only)
Read the analysis (Swedish)


Successful DRP prediction of patients treated with 2X-121, the PARP inhibitor from Eisai



Oncology Venture and Eisai Forge Exclusive Global License Agreement for Clinical Stage Oncology Drug PARP Inhibitor E7449 / 2X-121

See Press release
Läs pressmeddelande


Successful prediction of Cancer response to LiPlaCis in Breast cancer and other tumors by OV’s DRP

See Press release
Läs pressmeddelande


OV`s second drug candidate in the clinic – First Multiple Myeloma patient in study with APO010

See Press release
Läs pressmeddelande


2X Oncology obtains US IND for 2X-111 a Liposomal doxorubicin

See Press release
Läs pressmeddelande


The efficacy of chemotherapy with epirubicin, one the of most used drugs in Breast Cancer can now be predicted by the DRP

See Press release
Läs pressmeddelande


2X Oncology Inc. presents at Jefferies Global Healtcare conference (live webcast)


Berlingske Business: Interview with CEO of Oncology Venture

Read the article


Interview with OV and MPI in ‘Millionærklubben’

Listen to the radio program


Latest articles from MedWatch (Danish)

19 January 2017: Oncology Venture får europæisk stjernebevilling


VD Peter Buhl video presentation at Sedermeradagen in Copenhagen 23. March

See the Video


Oncology Venture secures seed financing for two SPVs & DRP Exclusivity



Oncology Venture: First DRP-positive breast cancer patient obtained reduction of tumor



Oncology Venture: Best Practice article on APO010

Download (In Danish only)

Presentation of OV by CEO Peter Buhl Jensen



Smallcap.se analysis of Oncology Venture




Peter Buhl Jensen talks about Oncology Venture – Radio24syv

Listen here – 10 July 2015
Listen here – 22 July 2015

Stock information

Latest (SEK)
High (SEK)
Low (SEK)

Updated on


DRP Technology Presentation

Doctor B


OV Company Presentation